hotspot -WSS

hotspot

author：knowledge 2025-10-07 23:09:27 - browse：722

Vertex Pharmaceuticals Inc. building — Craig F. Walker/The Boston Globe

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.

The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

“The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Wellcome Trust names Røttingen as its new CEO

knowledge

WSS

How doctors and nurses shape Google's AI

Medicare to cover more brain scans related to Alzheimer’s drugs

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

What the Wegovy shortage looks like for doctors — and for patients

Celiac disease study examines precisely how gluten triggers injury

Involuntary treatment for addiction doesn't work

entertainment

hotspot

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Moonlake's readout produced a cash windfall. Risks remain

Nick Jonas talks about managing diabetes along with his career

The cancer drug shortage isn’t new — and neither are the solutions

Argenx drug significantly slows progression of nerve disorder

Affirmative action in medical school literally saved lives

Who gets to use the title 'doctor'?

Psychedelics group wrestles with new pharma identity

How doctors and nurses shape Google's AI

explore

Care demand spikes challenge UnitedHealth’s provider arm

Better Therapeutics data on benefit with GLP

J&J expands global access to TB drug amid advocacy campaign

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

The new HIV moral panic

European regulators consider appeal over Amylyx ALS drug

entertainment

leisure time

knowledge

hotspot